Transplantation for Cholangiocarcinoma

Clinics in Liver Disease

Volumn 15, Issue 4, 2011, Pages 699-715

  Masuoka, Howard C ^a   Rosen, Charles B ^b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Acute cholangitis; Biliary stenting; Biliary stricture; Cholangiocarcinoma; Klatskin tumor; Liver transplantation; Living donor liver transplantation; Neoadjuvant therapy

Indexed keywords

CISPLATIN; FLUOROURACIL; GEMCITABINE; SORAFENIB; SUNITINIB;

BILE DUCT CARCINOMA; BILE DUCT OBSTRUCTION; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; DISEASE CLASSIFICATION; HUMAN; LIVER TRANSPLANTATION; PATHOPHYSIOLOGY; REVIEW; RISK FACTOR;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; HUMANS; INCIDENCE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; NEOPLASM STAGING; PALLIATIVE CARE; RISK FACTORS; TREATMENT OUTCOME;

EID: 80054957121     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2011.08.004     Document Type: Review

References (59)

1. Khan S.A., Taylor-Robinson S.D., Toledano M.B., et al. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002, 37(6):806-813.
2. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology 2001, 33(6):1353-1357.
3. Patel T. Worldwide trends in mortality from biliary tract malignancies. BMC Cancer 2002, 2:10.
4. Shaib Y.H., Davila J.A., McGlynn K., et al. Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?. J Hepatol 2004, 40(3):472-477.
5. Shaib Y., El-Serag H.B. The epidemiology of cholangiocarcinoma. Semin Liver Dis 2004, 24(2):115-125.
6. Bergquist A., Ekbom A., Olsson R., et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002, 36(3):321-327.
7. Burak K., Angulo P., Pasha T.M., et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004, 99(3):523-526.
8. Broome U., Olsson R., Loof L., et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996, 38(4):610-615.
9. Rosen C.B., Nagorney D.M., Wiesner R.H., et al. Cholangiocarcinoma complicating primary sclerosing cholangitis. Ann Surg 1991, 213(1):21-25.
10. Chalasani N., Baluyut A., Ismail A., et al. Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology 2000, 31(1):7-11.
11. Shin H.R., Lee C.U., Park H.J., et al. Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea. Int J Epidemiol 1996, 25(5):933-940.
12. Vatanasapt V., Uttaravichien T., Mairiang E.O., et al. Cholangiocarcinoma in north-east Thailand. Lancet 1990, 335(8681):116-117.
13. Mecklin J.P., Jarvinen H.J., Virolainen M. The association between cholangiocarcinoma and hereditary nonpolyposis colorectal carcinoma. Cancer 1992, 69(5):1112-1114.
14. Lee S.S., Kim M.H., Lee S.K., et al. Clinicopathologic review of 58 patients with biliary papillomatosis. Cancer 2004, 100(4):783-793.
15. Lipsett P.A., Pitt H.A., Colombani P.M., et al. Choledochal cyst disease. A changing pattern of presentation. Ann Surg 1994, 220(5):644-652.
16. Edil B.H., Cameron J.L., Reddy S., et al. Choledochal cyst disease in children and adults: a 30-year single-institution experience. J Am Coll Surg 2008, 206(5):1000-1005. [discussion: 1005-8].
17. El-Serag H.B., Engels E.A., Landgren O., et al. Risk of hepatobiliary and pancreatic cancers after hepatitis C virus infection: a population-based study of U.S. veterans. Hepatology 2009, 49(1):116-123.
18. Nakajima T., Kondo Y., Miyazaki M., et al. A histopathologic study of 102 cases of intrahepatic cholangiocarcinoma: histologic classification and modes of spreading. Hum Pathol 1988, 19(10):1228-1234.
19. Chen T.C., Ng K.F., Kuo T. Intrahepatic cholangiocarcinoma with lymphoepithelioma-like component. Mod Pathol 2001, 14(5):527-532.
20. Iguchi T., Yamashita N., Aishima S., et al. A comprehensive analysis of immunohistochemical studies in intrahepatic cholangiocarcinoma using the survival tree model. Oncology 2009, 76(4):293-300.
21. Lau S.K., Prakash S., Geller S.A., et al. Comparative immunohistochemical profile of hepatocellular carcinoma, cholangiocarcinoma, and metastatic adenocarcinoma. Hum Pathol 2002, 33(12):1175-1181.
22. Patsenker E., Wilkens L., Banz V., et al. The alphavbeta6 integrin is a highly specific immunohistochemical marker for cholangiocarcinoma. J Hepatol 2010, 52(3):362-369.
23. Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. An unusual tumor with distinctive clinical and pathological features. Am J Med 1965, 38:241-256.
24. Bismuth H., Corlette M.B. Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. Surg Gynecol Obstet 1975, 140(2):170-178.
25. De Bellis M., Sherman S., Fogel E.L., et al. Tissue sampling at ERCP in suspected malignant biliary strictures (part 1). Gastrointest Endosc 2002, 56(4):552-561.
26. Baron T.H., Harewood G.C., Rumalla A., et al. A prospective comparison of digital image analysis and routine cytology for the identification of malignancy in biliary tract strictures. Clin Gastroenterol Hepatol 2004, 2(3):214-219.
27. Clary B., Jarnigan W., Pitt H., et al. Hilar cholangiocarcinoma. J Gastrointest Surg 2004, 8(3):298-302.
28. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol 1990, 85(4):350-355.
29. Nichols J.C., Gores G.J., LaRusso N.F., et al. Diagnostic role of serum CA 19-9 for cholangiocarcinoma in patients with primary sclerosing cholangitis. Mayo Clin Proc 1993, 68(9):874-879.
30. Okabayashi T., Yamamoto J., Kosuge T., et al. A new staging system for mass-forming intrahepatic cholangiocarcinoma: analysis of preoperative and postoperative variables. Cancer 2001, 92(9):2374-2383.
31. Jarnagin W.R., Fong Y., DeMatteo R.P., et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 2001, 234(4):507-517. [discussion: 517-9].
32. Deoliveira M.L., Schulick R.D., Nimura Y., et al. New staging system and a registry for perihilar cholangiocarcinoma. Hepatology 2011, 53(4):1363-1371.
33. Valle J., Wasan H., Palmer D.H., et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010, 362(14):1273-1281.
34. Bengala C., Bertolini F., Malavasi N., et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer 2010, 102(1):68-72.
35. Gruenberger B., Schueller J., Heubrandtner U., et al. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol 2010, 11(12):1142-1148.
36. Lubner S.J., Mahoney M.R., Kolesar J.L., et al. Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II consortium study. J Clin Oncol 2010, 28(21):3491-3497.
37. Prat F., Chapat O., Ducot B., et al. Predictive factors for survival of patients with inoperable malignant distal biliary strictures: a practical management guideline. Gut 1998, 42(1):76-80.
38. Zoepf T., Jakobs R., Arnold J.C., et al. Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy. Am J Gastroenterol 2005, 100(11):2426-2430.
39. Kiefer M.V., Albert M., McNally M., et al. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, Ethiodol, and polyvinyl alcohol: a 2-center study. Cancer 2011, 117(7):1498-1505.
40. Stieber A.C., Marino I.R., Iwatsuki S., et al. Cholangiocarcinoma in sclerosing cholangitis. The role of liver transplantation. Int Surg 1989, 74(1):1-3.
41. Goere D., Wagholikar G.D., Pessaux P., et al. Utility of staging laparoscopy in subsets of biliary cancers: laparoscopy is a powerful diagnostic tool in patients with intrahepatic and gallbladder carcinoma. Surg Endosc 2006, 20(5):721-725.
42. Lai E.C.H., Lau W.Y. Aggressive surgical resection for hilar cholangiocarcinoma. ANZ J Surg 2005, 75(11):981-985.
43. Nagorney D.M., Donohue J.H., Farnell M.B., et al. Outcomes after curative resections of cholangiocarcinoma. Arch Surg 1993, 128(8):871-877. [discussion: 870-9].
44. Murakami Y., Uemura K., Sudo T., et al. Prognostic factors after surgical resection for intrahepatic, hilar, and distal cholangiocarcinoma. Ann Surg Oncol 2011, 18(3):651-658.
45. Nakeeb A., Tran K.Q., Black M.J., et al. Improved survival in resected biliary malignancies. Surgery 2002, 132(4):555-563. [discussion: 563-4].
46. Uenishi T., Hirohashi K., Kubo S., et al. Histologic factors affecting prognosis following hepatectomy for intrahepatic cholangiocarcinoma. World J Surg 2001, 25(7):865-869.
47. Uenishi T., Hirohashi K., Kubo S., et al. Clinicopathological factors predicting outcome after resection of mass-forming intrahepatic cholangiocarcinoma. Br J Surg 2001, 88(7):969-974.
48. Rea D.J., Munoz-Juarez M., Farnell M.B., et al. Major hepatic resection for hilar cholangiocarcinoma: analysis of 46 patients. Arch Surg 2004, 139(5):514-523. [discussion: 523-5].
49. Kelley S.T., Bloomston M., Serafini F., et al. Cholangiocarcinoma: advocate an aggressive operative approach with adjuvant chemotherapy. Am Surg 2004, 70(9):743-748. [discussion: 748-9].
50. Pitt H.A., Nakeeb A., Abrams R.A., et al. Perihilar cholangiocarcinoma. Postoperative radiotherapy does not improve survival. Ann Surg 1995, 221(6):788-797. [discussion: 797-8].
51. Iwatsuki S., Todo S., Marsh J.W., et al. Treatment of hilar cholangiocarcinoma (Klatskin tumors) with hepatic resection or transplantation. J Am Coll Surg 1998, 187(4):358-364.
52. Jonas S., Kling N., Guckelberger O., et al. Orthotopic liver transplantation after extended bile duct resection as treatment of hilar cholangiocarcinoma. First long-terms results. Transpl Int 1998, 11(Suppl 1):S206-S208.
53. Shimoda M., Farmer D.G., Colquhoun S.D., et al. Liver transplantation for cholangiocellular carcinoma: analysis of a single-center experience and review of the literature. Liver Transpl 2001, 7(12):1023-1033.
54. Heimbach J.K., Gores G.J., Haddock M.G., et al. Liver transplantation for unresectable perihilar cholangiocarcinoma. Semin Liver Dis 2004, 24(2):201-207.
55. Sudan D., DeRoover A., Chinnakotla S., et al. Radiochemotherapy and transplantation allow long-term survival for nonresectable hilar cholangiocarcinoma. Am J Transplant 2002, 2(8):774-779.
56. Rea D.J., Heimbach J.K., Rosen C.B., et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg 2005, 242(3):451-458. [discussion: 458-61].
57. De Palma G.D., Galloro G., Siciliano S., et al. Unilateral versus bilateral endoscopic hepatic duct drainage in patients with malignant hilar biliary obstruction: results of a prospective, randomized, and controlled study. Gastrointest Endosc 2001, 53(6):547-553.
58. Mantel H.T., Rosen C.B., Heimbach J.K., et al. Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma. Liver Transpl 2007, 13(10):1372-1381.
59. Heimbach J.K. Successful liver transplantation for hilar cholangiocarcinoma. Curr Opin Gastroenterol 2008, 24(3):384-388.